The peripheral benzodiazepine receptor (PBR) is a trans-mitochondrial membrane protein that modulates steroid biosynthesis. Recently, up-regulation and nuclear localization of PBR has been shown to be associated with colon, prostate, and breast cancer. PBR has been targeted by the exogenous synthetic ligand,
Introduction
Genetically engineered mouse models of human cancer represent a significant advance over conventional nude mouse xenograft models because it is possible to mimic features of human cancer development and progression by discrete spatial and temporal targeting of genetic events to distinct organs in the mouse. Adding to the relevance of these models, tumors from genetically engineered mouse models arise in immunocompetent hosts and are exposed to local factors of disease such as gut flora in the case of intestinal tumors. Among such models, Smad3 tm1parÀ/À (hereafter referred to as Smad3 À/À mice; ref. 1) have been shown to develop colonic tumors, including carcinomas, that exhibit a marked inflammatory component. In a recent advance, a single dose of azoxymethane has been coupled with the administration of dextran sulfate (DSS), which results in colonic inflammation (2) and then cancer. This combined approach produces cancers within the context of an inflammatory microenvironment, which has been shown to promote carcinogenesis in the gut (3, 4) .
Preclinical assessment of tumor development and progression, as well as response to therapeutic intervention, in intestinal tumor models is currently limited by the lack of noninvasive methodologies suitable for evaluating the tumor. Thus, direct tumor assessment in these models requires sacrificing the animals, which complicates experimental protocols and significantly increases the number of animals required. Recently, others have reported advancement in the imaging of colonic tumors by contrast-enhanced computed tomography (CT) (5, 6) and by contrast-enhanced magnetic resonance imaging (MRI) (6) . These techniques, while useful, remain low throughput and inherently invasive due to the necessity for purging, refilling, and suturing of the bowel to provide adequate contrast between the lumen of the bowel and the bowel wall. The development of accurate, low-cost, high-throughput, noninvasive imaging strategies capable of identifying tumor onset and progression, as well as response to treatment, remains an important goal toward rapid translation of innovative diagnostics and therapeutics.
The recent influx of low-cost instrumentation and novel molecular imaging reagents (7, 8) designed to operate within the tissue-transparent near-IR (NIR) window has enabled rapid, systemic, deep tissue targeting of tumors in small animals. In this study, we developed a novel NIR imaging agent, NIRconPK11195, to target the peripheral benzodiazepine receptor (PBR), which is up-regulated in late-stage colon cancer (9) . PBR is primarily associated with mitochondrial steroidogenesis and has been shown to be up-regulated in the epithelial component of cancers of the colon, breast, and prostate (10), as well as in activated macrophages in the brain (11, 12) . The PBR synthetic ligand, PK11195, has been used clinically to image inflammation associated with several neurologic diseases (13) (14) (15) . Con-PK11195, an analogue of the widely used PBR ligand PK11195, was recently prepared (16) and shown to be useful as a targeting agent for fluorescent probes as well as bimodal lanthanide chelate-imaging agents (17) .
Here, we prepared a NIR fluorophore-labeled version of the ligand, NIR-conPK11195, and tested it as a targeted imaging agent for colonic tumors in Smad3 À/À mice. The accuracy of detecting colonic tumors was assessed by imaging a total of 37 mice [Smad3 À/À (n = 25), Smad3 +/À (n = 7), and Smad3
Using fluorescence signal-to-noise ratio of z4-fold 13 h after injection of labeled ligand, the sensitivity and specificity of detecting adenomas and carcinomas were 67% and 86%, respectively. By this operationally defined criterion, small, flat lesions with invasive properties were detected but not benign tumors, chronically inflamed colon, or experimentally induced colonic inflammation. Overall, the imaging strategy we present provides a widely applicable, rapid, and inexpensive means of detecting colonic adenomas and carcinomas in the background of benign tumors and/or inflammation.
Results
Given the putative clinical relevance of PBR expression in human colon cancer (9), we queried PBR gene expression data from 39 colonic tumors derived from four distinct mouse models of intestinal neoplasia, including Smad3 À/À (n = 13), azoxymethane-induced (n = 14), APC Min+/À (n = 9), and transforming growth factor h À ;Rag2 À/À tumors (n = 3). Expression values for 28,000 genes of known function were compared with those from wild-type (WT) adult C57BL6/J colons (n = 3). We found upregulation of PBR expression in Smad3 À/À tumors (mean log fold increase over adult WT colon = 3.6; SD, F0.9), azoxymethane-induced tumors (mean log fold increase over adult WT colon = 3.0; SD, F1.6), APC Min/+ tumors (mean log fold increase over adult WT colon = 4.8; SD, F3.3), and transforming growth factor h À/À Â Rag2 À/À tumors (mean log fold increase over adult WT colon = 4.3; SD, F0.8; Supplementary  Fig. S1A ). Network analysis of gene expression changes clustering with respect to PBR up-regulation was conducted. This analysis indicated that PBR is coordinately regulated with genes that have emerged as master regulatory nodes in colon cancer such as p53, CEBP/h, and signal transducers and activators of transcription 3, and that it links to these nodes directly downstream of Myc ( Supplementary Fig. S1B ).
To develop an optical imaging agent capable of rapid and high-throughput imaging of deep-tissue PBR-expressing tumors, we labeled our novel analogue of the PBR ligand, con-PK11195 (16, 17) , with a NIR fluorophore yielding the molecular imaging agent NIR-conPK11195 (Fig. 1A) . The aqueous media spectroscopic properties of the resulting agent are shown in Fig. 1B , with excitation (k max = 780 nm) and emission (k max = 800 nm) centered within the tissue transparency window.
We next tested NIR-conPK11195 for specific retention in colonic tumors using 37 Smad3 À/À , Smad3 +/À , and Smad3
littermates between 2 and 5 months of age. For these experiments, we empirically selected a signal-to-noise ratio of z4-fold at 13 h after injection of labeled ligand as a cutoff for the prediction of the presence of tumor in the Smad3 À/À mice. Using this operationally defined criterion, we evaluated NIRconPK11195 signal retention in this cohort of mice. The results of this analysis are summarized in Table 1 . Of the 37 animals tested, 15 harbored tumors, and 10 of these retained foci of NIR-conPK11195 fluorescent signal, thus producing 67% sensitivity (10/15) for tumor detection. Among the 22 nontumor-bearing mice, only 3 retained foci of NIR-conPK11195 fluorescent signal 4-fold or higher above background, thus producing 86% specificity (19/22) for tumor detection.
To determine the kinetics of NIR-conPK11195 in live animals, we conducted clearance profile analyses upon the full set of animals. For these experiments, 10 nmol of the agent was given i.v., and images were recorded before administration and at timed intervals up to 20 h postadministration ( Fig. 2A) . In Fig. 2B , we show a plot of the clearance profiles for agematched Smad3 +/+ (left mouse) and Smad3 À/À (right mouse) mice shown in Fig. 2A , using a uniform region of interest (ROI) to collect photon counts in the abdomen at locations avoiding the gall bladder where high focal background occurs (see ROI depicted in Fig. 2A ). As can be seen, we observed little difference in focal fluorescent retention between control and Smad3 À/À mice at early time points postadministration (<4 h) of NIR-conPK11195. However, between 4 and 7 h postadministration, the agent accumulated rapidly in the Smad3 À/À mice and exhibited localized abdominal retention (z4-fold over background per uniform ROI). Subsequently, the fluorescence intensity in both Smad3
À/À and control animals gradually decreased, returning to background levels by 20 h postadministration. The presence or absence of colonic tumors in H&E-stained slides of intestinal ''Swiss Rolls'' was assessed by a pathologist (M.K. Washington), and PBR expression in the tumors was confirmed by immunohistochemistry. Here, strong nuclear staining of PBR can be seen in the epithelial component of intestinal tumors (Fig. 2D) , consistent with published results (18) . In contrast, there was weaker and more heterogeneous staining for PBR in normal colonic mucosa taken from control littermates (Fig. 2C) .
To further examine the specificity of NIR-conPK11195 for tumors, the retention of free (unconjugated) NIR dye (LI-COR 800CW) was compared with the targeted chemistry (NIRconPK11195) in Smad3
À/À tumor-bearing animals. Images shown in Fig. 3 illustrate that free dye does not accumulate in the colons of tumor-bearing Smad3 À/À mice following i.v. administration, nor does it produce signal at either low or high resolution ( Fig. 3A and B, bottom). Furthermore, fluorescence of the free dye is comparable to control mice ( Fig. 3A and B, top) signals. We also found that the free dye is rapidly cleared through the urinary tract and not through the hepatobiliary system, as is NIR-conPK11195 (data not shown). As seen in Fig. 3 , high-resolution fluorescent imaging of excised colonic tissues following in vivo administration of the free dye or NIRconPK11195 indicate ligand-specific focal retention in colonic cancer lesions intestinal at 13 h postadministration ( Fig. 3B and E, top and bottom). Unconjugated LI-COR 800CW did not accumulate to a significant extent or colocalize with colonic tumors, nor did it accumulate in non -tumor-bearing animals ( Fig. 3A -C, top and bottom ). A clearance profile for representative tumor-bearing mice, shown in Fig. 3G , illustrates the relative photon flux per uniform ROI over time and shows ligand-specific retention of the agent. Therefore, accumulation and colocalization of NIR-conPK11195 is ligand dependent and is not due to nonspecific association with biological properties related to the tumor such as leaky vasculature.
To compare the optical imaging strategy with a more conventional imaging methodology, we imaged a set of Smad3 +/+ and Smad3 À/À animals using Fig. 4 . We observed a good correlation between optical imaging using NIR-conPK11195 and PET imaging with 18 FDG for tumor detection in Smad3 À/À mice. The presence of tumors could be detected using either imaging strategy at comparable resolution.
Upon close examination, we found variation in histopathology of tumors between Smad3 À/À and Smad3 +/À mice. This variation had apparent effects on the quantification of retained NIR-conPK11195 in these mice. Figure 5 shows a representative imaging experiment of Smad3 À/À and Smad3 +/À mice with accompanying histopathologic findings. As expected, we found adenomas and carcinomas in the Smad3 À/À mice. In addition, benign lesions, such as hamartomas (Fig. 5B, top) , and cystic lesions were identified only in Smad3 heterozygous mice. In live animal imaging, the NIR-conPK11195 fluorescent signature suggested varying degrees of labeling intensity among these mice. Representative examples show that benign hamartomas retained signal in the range of 1 to 2 Â 10 8 photon flux per second (fps) (Fig. 5A, top) , adenomas retained intermediate signal in the range of 2 to 3 Â 10 8 fps (Fig. 5A , middle), and carcinomas retained signal above 3.5 Â 10 8 fps (Fig. 5A, bottom) . It is important to note that Smad3 À/À animals with heavy tumor burden exhibited runting, resulting in a shorter path length for light to travel from the tumor through tissue, thus increasing the relative photon flux impinging onto the detector and complicating signal quantification between genotypes. Strategies to normalize signal to animal size should improve the quality of the information derived from deep tissue tumors and are currently under investigation.
In an effort to determine the effectiveness of detecting early lesions by NIR-conPK11195 imaging, we screened a panel of young Smad3
À/À mice (aged 2 to 4 months). Because carcinomas in Smad3 À/À mice are preceded by inflammation and dysplasia, these analyses allowed us to determine whether NIRconPK11195 distinguished inflammation and dysplasia from cancer. As shown in Fig. 6A , NIR-conPK11195 was not retained in young Smad3 À/À animals harboring significant inflammation, associated mucosal thickening, or dysplasia. One 4-month-old mouse in this group retained significant z4-fold (over background) NIR-conPK11195. Although initially overlooked by gross inspection, a single flat (sessile) adenocarcinoma was detected histologically in the excised tissue from this mouse (Fig. 6B , right, boundaries of tumor outlined by arrows). The invasive properties of this lesion were subsequently confirmed by our pathologist (M.K. Washington). This result suggests enhanced specificity of NIR-conPK11195 for invasive lesions, as suggested in Fig. 5 and will serve as the basis for further study on the role of PBR expression in tumor cell behavior.
Expression of PBR protein has been shown to be upregulated in activated macrophages of the brain (11, 12) . To determine whether NIR-conPK11195 would be retained by intestinal inflammation, we administered NIR-conPK11195 to WT mice with colonic inflammation induced by a 7-day course of DSS in their drinking water according to the method of Cooper et al. (19) . In these experiments, DSS-treated WT mice were imaged alongside untreated Smad3 À/À mice. We found that significant NIR signal appeared abdominally at 4 and 8 h postadministration of NIR-conPK11195 in both tumor-bearing Smad3 À/À and in DSS-treated WT animals. However, that fluorescent signal was retained at 13 h postadministration only in tumor-bearing animals (Fig. 7A) . Strikingly, a rapid clearance of NIR signal occurred in the DSS-treated mice beginning between 4 and 8 h postadministration, as can be seen in the clearance profile (Fig. 7C) . By 12 h postadministration, NIR signal returned to background levels in the DSS-treated mice, but not in the tumor-bearing Smad3 À/À mice ( Fig. 7A and B, top and bottom). Figure 7C depicts the mean fluorescence profile for DSS-treated and tumor-bearing mice between NIRconPK11195 administration and 12 h thereafter. As can be seen in this profile, a 6-fold difference in signal was observed between Smad3
À/À and DSS-treated WT mice. Upon tissue resection, we found patchy acute inflammation in sections from all DSS-treated animals accompanied by significant crypt degeneration, attenuated crypts, and significant loss of epithelium (Fig. 7B, bottom) . Carcinomas were confirmed histologically for all Smad3 À/À mice (Fig. 7B, top) . Collectively, these data indicate that temporal behavior of NIRconPK11195 retention can be used to discriminate neoplastic tissue from inflammation in Smad3 À/À mice.
Discussion
We tested the effectiveness of a NIR-conPK11195 -targeted imaging strategy in the Smad3
À/À mouse model of intestinal cancer (for a review of the histopathology of these tumors as well as those from other experimental models of intestinal neoplasia, see ref.
20). Smad3
À/À mice develop mucinous invasive carcinomas of the colon with a strong inflammatory component. We queried global tumor expression profiles from four mouse models of intestinal neoplasia for PBR expression. We found that PBR overexpression was uniformly up-regulated in mouse colonic tumors from all four mouse models. We did network analysis on a cluster of 11 genes that were coordinately regulated with PBR and found that 10 of these genes organized into a single network (Supplementary Fig. S1 ). This network analysis shows that PBR expression is regulated downstream of c-myc, and that its overexpression may serve as a broad marker for neoplasia and, thus, as a widely applicable imaging target. Therefore, we decided to use a NIR conjugate of the PBR ligand, PK11195, to test a targeted optical imaging strategy for colonic tumor detection in Smad3 À/À mice. This strategy was sensitive and specific for colonic tumors and allowed us to rapidly screen a large cohort of mice for the presence of tumors on a background of colonic inflammation.
As illustrated in Fig. 2 , we found by immunohistochemistry that overexpression of PBR in colonic tumors from Smad3 who have observed this phenomenon in both breast and in liver cancer cells. Although the role of nuclear PBR has not been precisely defined, it has been shown to exert an effect upon cellular proliferation in MDA-231 breast cancer cells (18) .
Multiple methods for noninvasive assessment of intestinal tumors in mouse models have emerged over the past several years (5, 6, 22) . The method presented here based on targeting PBR expression combines the low-cost, high-throughput advantages of optical methods based on bioluminescence, yet avoids the requirement for a reporter transgene enhancing the potential for translational usefulness. Although optical strategies have drawbacks in terms of spatial resolution and signal quantitation, we found these limitations to be comparable to those encountered with 18 FDG-PET/CT imaging (Fig. 4) . Notably, however, the high-throughput nature of the optical screening strategy enabled high-throughput screening (up to 60 animals per hour is possible), whereas only a few animals could be screened by PET/CT imaging in a comparable time frame. Furthermore, screening the animals with optical imaging was accomplished at a fraction of the cost of PET/CT imaging, without the added complications of lengthy anesthesia or for the introduction of ionizing radiation. The advantage of this strategy lies in the fact that large populations of mice can be taken through an inexpensive and noninvasive screen, and more invasive and costly contrast-enhanced methods (PET, CT, or MRI) would be reserved for the subset of animals harboring tumors when appropriate. With respect to screening for the presence of colorectal cancer, the specificity (86%) and sensitivity (67%) reported here compares favorably with that obtained with comparable 18 FDG-PET data in humans reported at 91% to 93% sensitivity and 63% to 83% specificity (refs. 23, 24 ; considering the relative experience of trained radiologists versus laboratory scientists). No data exist to date regarding the detection specificity or sensitivity for intestinal lesion by 18 FDG-PET in mouse models. The role of inflammation in cancer development is an area of intense investigation (2, 3) . Previous studies have shown a high level of PBR expression in activated macrophages associated with inflammation (13, 25) , so it was important for us to rule out nonspecific retention of the targeted agent related to tumorassociated inflammatory processes. We found that retention profiles of NIR-conPK11195 discriminated between mice treated with DSS and tumor-bearing mice at times between 8 and 13 h postadministration (Fig. 7C) . Furthermore, we found that young mice exhibiting precancerous inflammation and associated epithelial dysplasia did not retain a NIR-conPK11195 (Fig. 6) ; however, in one animal from this group of younger animals, the presence of an invasive lesion correlated with significant NIR retention. Thus, NIR-conPK11195 represents an imaging agent that could be used to screen cohorts of mice during tumor development, even on the background of accompanying or experimentally induced inflammation.
The ability to follow molecular events in vivo represents a paradigm shift for medical science. A critically important goal of molecular imaging studies is to detect spontaneously arising tumors in the context of the host/tumor microenvironment (4).
Smad3
À/À mice exhibit many of the features of the tumor microenvironment of human colon cancer and, thus, represent an opportunity to study molecular features of disease progression and to assess therapeutic efficacy in preclinical trials. In a step toward these goals, we have shown an inexpensive, highthroughput strategy for in vivo molecular imaging of spontaneous intestinal neoplasia. Our ongoing efforts are directed toward preparing con-PK11195 analogues containing 99 Tc or 64 Cu to facilitate PBR targeting in clinically relevant imaging modalities, such as single-photon emission computed tomography (SPECT) and PET with the long-term goal of improving the early diagnosis of colon cancer. Additionally, we expect these agents to be useful for noninvasive monitoring of therapeutic efficacy that should be useful in improving clinical outcomes. These agents would be expected to achieve greater sensitivity and specificity than seen in this study when used in conjunction with detectors that have tomographic capability such as PET or SPECT.
Materials and Methods

Microarray
Data for PBR gene expression were obtained from a mouse colon tumor gene expression database composed of mouse tumors collected through the Mouse Models of Human Cancers Consortium. 10 Individual colonic tumors from individually Genetics, and 1,000 custom clones (28,000 cDNA elements total). Briefly, individual RNA samples were labeled with Cy5 as described by Park (26) , and a universal reference RNA (day E17.5 whole mouse) was labeled with Cy3, hybridized to individual microarrays. Individual arrays were normalized by the Lowess intensity-dependent correction, and relative gene expression levels were estimated by dividing individual gene signal ratios by that of the average of adult mouse colon samples. Gene network analysis was done using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA).
Chemistry
Con-PK11195 was synthesized as described previously (16) . LI-COR-800CW was purchased from LI-COR Biosciences (Lincoln, NE). Briefly, the dye and the conPK11195 derivative were dissolved by stirring in dry DMSO in an argon-flushed vessel. The reaction was protected from room light and allowed to proceed at room temperature overnight. Reaction progress was followed with reverse-phase HPLC using a C18 column and acetonitrile/water as the eluent. NIR-conPK11195 was purified on an open, alumina column eluting with acetonitrile/ water, followed by an ion-exchange column eluting with water. Pure fractions were then concentrated using rotary evaporation and further concentrated with lyopholization. The imaging agent was characterized by nuclear magnetic resonance and electrospray ionization mass spectrometry calculated (found): 1364.01 (M 2+ 681.95). Spectroscopic characterization in both water and DMSO consisted of both UV -visible light and fluorometry.
Mouse Models
Smad3 À/À mice were maintained according to institutional guidelines. Induction of inflammation in mice was obtained according to the method of Cooper et al. (19) . Briefly, adult mice were fed DSS (MW 40-50 kDa; U.S. Biochemical Co., Cleveland, OH) at 2.5% in the drinking water for 7 days at which time consumption of normal drinking water was resumed. Mice were imaged at days 9, 13, and 16 after commencement of the DSS treatment and sacrificed thereafter. Excised tissues were imaged on the Odyssey NIR imaging system (LI-COR Biosciences) using an 800-nm filter. Following ex vivo imaging, tissues were fixed in 4% paraformaldehyde for 8 to 12 h before dehydration in 70% ethanol and then paraffin embedded. H&E-stained slides were prepared, and pathology was ascertained by an experienced gastrointestinal pathologist (M.K. Washington).
Imaging Systems
Following i.v. administration of 10 nmol of NIRconPK11195, in vivo imaging was carried out in a Xenogen IVIS 200 imaging system (Alameda, CA), equipped with a ventilator. Animals were anesthetized for imaging using 1.2% isoflurane (Baxter Pharmaceuticals, Deerfield, IL) in O 2 at 2 L/ min. Body temperature was maintained using a thermostatcontrolled heating pad. The Odyssey imaging system (see above) was used to image excised tissues using the 800-nm channel and 1-mm focus offset. Resolution and laser intensity were conserved during quantitative experiments.
For quantification of optical signal, uniform ROIs were created using the Xenogen software package. ROI area was conserved for each experiment, and the total photon flux was determined for individual ROIs. Signal-to-noise ratio was determined by dividing the ROI intensity for an experimental animal by the ROI intensity for the control animal. and FDG were timed such that imaging with the PET system immediately followed imaging with the CT system. A single imaging cradle, interchangeable with the CT and PET, was used such that mice could be imaged by both systems sequentially with minimal change in positioning. This imaging cradle had four fiducial markers that could be identified in both the PET and CT images. Image registration based on rigid-body alignment of these fiducials was achieved using the software package, Amide (27) .
Histologic Analysis
Intestinal tissue was examined in situ for evidence of macroscopic tumors (>1 mm diameter). Sections of intestine were washed and prepared as a Swiss roll before preservation in 4% paraformaldehyde and subsequently paraffin embedded and sectioned for H&E staining. Five-micrometer tissue sections for immunohistochemistry were prepared as previously described (28) . Primary rabbit anti-PBR polyclonal antibody (a generous gift from V. Papadopoulos, Georgetown University, Washington, DC) or anti-bromodeoxyuridine antibody (Accurate Chemical and Scientific Co., Westbury, NY) were used to stain sections using the Vectastin Elite ABC kit (Vector Laboratories, Burlingame, CA).
